The Cancer Research UK Barts Centre at Queen Mary University of London (QMUL) has received an award of over £10 million to renew its status as an official CRUK Centre.
Almost a doubling of its previous investment, the funds will support research facilities and training programmes for research students, with the aim to of getting treatments and diagnostics to cancer patients sooner.
Professor Nick Lemoine, Director of QMUL’s Barts Cancer Institute, said: "This renewed funding for our Cancer Research UK Barts Centre will have such a significant impact on all of us and the patients that we work towards helping, as well as the wider scientific community, through our research.
"It is wonderful to have the work performed by our research and support staff, world-class in its excellent quality, recognised through this award, and it is a great honour for us to receive it. Thank you from all of us to Cancer Research UK and its supporters."
The main objective of the CRUK Barts Centre is to ensure that research conducted will benefit cancer patients, primarily by:
Sir Harpal Kumar, chief executive of Cancer Research UK, said: "Together, these Centres accelerate the discovery and development of better treatments for cancer patients. They are a unique opportunity for collaboration, both locally across universities and hospitals, and nationally across the network of Centres.
"This is an exciting time for cancer research. Emerging treatments like immunotherapy are radically changing the field, we are increasingly able to tailor more treatments to individual patients, and advances in technology mean we can collect and share more research data than ever before."
The other Cancer Research UK Centres are in: Birmingham; Cambridge; Edinburgh; Glasgow; Manchester; Newcastle; Oxford; Southampton and London - Imperial College; Institute of Cancer Research, King’s College and UCL.
For media information, contact: